Comparison of Amitriptyline and US Food and Drug Administration–Approved Treatments for Fibromyalgia

Farag, H; Yunusa, Ismaeel; Goswami, Hardik; Sultan, I.; Doucette, Joanne; Eguale, Tewodros

doi:10.1001/jamanetworkopen.2022.12939

Cited by 38 publications

(27 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En un estudio resiente de Farag y cols., publicado en 2022, se analizó mediante una revisión sistemática y un metanálisis en red las diferentes intervenciones farmacológicas para fibromialgia, considerando diferentes aspectos sintomáticos individuales de la enfermedad que pueden condicionar la respuesta clínica (Figura 1) (7).…”

Section: Correspondenciaunclassified

“…El estudio incluyó diferentes análisis que incluían desenlaces terapéuticos y aceptación a la intervención de medicamentos como amitriptilina, pregabalina, duloxetina y milnacipran en diferentes posologías y en comparación con una intervención placebo. El primer análisis realizado fue sobre la mejoría del dolor, incluyendo 35 estudios con 11.423 pacientes en total, encontrando que en comparación con el placebo la duloxetina a dosis de 120 mg era la intervención más efectiva, seguida por pregabalina de 450 mg. Por otra parte, el milnacipran de 100 mg reportó la menor reducción en dolor, aportando además un cálculo de área bajo la curva de probabilidad de rango acumulativo (SUCRA) para la duloxetina 120 mg de 99,1 % y pregabalina 450 de 86,8 %, valores asociados con mayor probabilidad de efectividad (7).…”

Section: Correspondenciaunclassified

“…La amitriptilina no tuvo diferencia en comparación con el placebo. En relación con el SUCRA, la duloxetina 120 mg tiene un valor del 88,4 %, duloxetina de 60 mg del 85,9 % y pregabalina de 600 mg del 80,3 % se asociaron con mayor probabilidad de efectividad (7).…”

Section: Correspondenciaunclassified

See 2 more Smart Citations

Intervenciones farmacológicas en fibromialgia, consideraciones actuales.

Gálvez¹,

Vega²

2022

Rev. Soc. Esp. Dolor.

View full text Add to dashboard Cite

Este es un archivo PDF de un manuscrito inédito que ha sido aceptado para su publicación en la Revista de la Sociedad Española del Dolor. Como un servicio a nuestros clientes estamos proporcionando esta primera versión del manuscrito en estado de pre-publicación. El manuscrito será sometido a la corrección de estilo final, composición y revisión de la prueba resultante antes de que se publique en su forma final. Tenga en cuenta que durante el proceso de producción se pueden dar errores lo que podría afectar el contenido final. El copyright y todos los derechos legales que se aplican al artículo pertenecen a la

show abstract

Section: Correspondenciaunclassified

See 1 more Smart Citation

Intervenciones farmacológicas en fibromialgia, consideraciones actuales.

Gálvez¹,

Vega²

2022

Rev. Soc. Esp. Dolor.

View full text Add to dashboard Cite

show abstract

“…[2] AMT has also been used in treatment of Fibromyalgia, an illness characterized by widespread chronic pain, physical exhaustion, cognitive difficulties and depressed mood. [3] Current pharmacotherapy often requires precise dosing of TCAs which can be individual to the patient. Therapeutic drug monitoring is considered by some a useful approach for compounds such as TCAs as these compounds can show variability in blood concentration amongst patients given the same dose.…”

Section: Introductionmentioning

confidence: 99%

“…Amitriptyline (AMT) is a traditional treatment used in clinical practice and its popularity is due to its high clinical effectiveness [2] . AMT has also been used in treatment of Fibromyalgia, an illness characterized by widespread chronic pain, physical exhaustion, cognitive difficulties and depressed mood [3] . Current pharmacotherapy often requires precise dosing of TCAs which can be individual to the patient.…”

Section: Introductionmentioning

confidence: 99%

Highly Sensitive and Selective Detection of the Antidepressant Amitriptyline Using a Functionalised Graphene‐Based Sensor

2022

View full text Add to dashboard Cite

The accurate measurement of drug concentration in patient samples is vital and is often conducted using point of care devices for therapeutic drug monitoring and other clinical activities. Two dimensional (2D) nanomaterials provide an opportunity to develop miniaturized, affordable and accurate drug sensors, with the promise of developing point of care tests, which are more convenient compared to current techniques that often require advanced instrumentation and laboratory tests. Here we present a reduced graphene oxidebased electrochemical sensor that permits precise measurements of amitriptyline, a well-known anti-depressant. The sensor uses functionalised graphene where amitriptyline selective receptors directly attached to the carbon atoms on the surface of the graphene through diels-alder reaction. The simplicity of the functionalisation procedure along with a tunable receptor used in this study implies that the same method can be used for developing similar selective sensors, simply by changing the small functional groups attached to the receptor molecule. The electrochemical characteristics of the functionalised graphene were studied with cyclic voltammetry, where the sensor demonstrated excellent selectivity, responding only to amitriptyline when tested against closely related tricyclic antidepressants and a range of other psychoactive drugs. The sensor displayed a wider linear range from 1 ng/mL to 80 μg/mL, which covers the concentration range for amitriptyline studied in therapeutic, pharmaceutical, and forensic investigations. The limit of detection of the developed sensor was 1 ng/ml which competes with the detection limit of gas chromatography -mass spectrometry investigated in this study.

show abstract

Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19

et al. 2022

View full text Add to dashboard Cite

ImportancePatients with COVID-19 have a high prevalence of diabetes, and diabetes and blood glucose control are determinants of intensive care unit admission and mortality.ObjectiveTo evaluate the association between COVID-19–related adverse outcomes and 8 antihyperglycemic drugs in patients with diabetes who were subsequently diagnosed and hospitalized with COVID-19.Data SourcesData were retrieved and collected in PubMed, Embase, Cochrane Central Register, Web of Science, and ClinicalTrials.gov from database inception to September 5, 2022.Study SelectionFor this systematic review and network meta-analysis, randomized clinical trials and observational studies conducted among patients with diabetes while receiving glucose-lowering therapies for at least 14 days before the confirmation of COVID-19 infection were included after blinded review by 2 independent reviewers and consultations of disagreement by a third independent reviewer. Of 1802 studies initially identified, 31 observational studies met the criteria for further analysis.Data Extraction and SynthesisThis study follows the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline. Bayesian network meta-analyses were performed with random effects.Main Outcomes and MeasuresA composite adverse outcome, including the need for intensive care unit admission, invasive and noninvasive mechanical ventilation, or in-hospital death.ResultsThirty-one distinct observational studies (3 689 010 patients with diabetes hospitalized for COVID-19) were included. The sodium-glucose cotransporter-2 inhibitors (SGLT-2is) were associated with relatively lower risks of adverse outcomes compared with insulin (log of odds ratio [logOR], 0.91; 95% credible interval [CrI], 0.57-1.26), dipeptidyl peptidase-4 inhibitors (logOR, 0.61; 95% CrI, 0.28-0.93), secretagogues (logOR, 0.37; 95% CrI, 0.02-0.72), and glucosidase inhibitors (logOR, 0.50; 95% CrI, 0.00-1.01). Based on the surface under the cumulative ranking curves value, SGLT-2is were associated with the lowest probability for adverse outcomes (6%), followed by glucagon-like peptide-1 receptor agonists (25%) and metformin (28%). A sensitivity analysis revealed that the study was reliable.Conclusions and RelevanceThese findings suggest that the use of an SGLT-2i before COVID-19 infection is associated with lower COVID-19–related adverse outcomes. In addition to SGLT-2is, glucagon-like peptide-1 receptor agonists and metformin were also associated with relatively low risk of adverse outcomes.

show abstract

Comparison of Amitriptyline and US Food and Drug Administration–Approved Treatments for Fibromyalgia

Cited by 38 publications

References 82 publications

Intervenciones farmacológicas en fibromialgia, consideraciones actuales.

Intervenciones farmacológicas en fibromialgia, consideraciones actuales.

Highly Sensitive and Selective Detection of the Antidepressant Amitriptyline Using a Functionalised Graphene‐Based Sensor

Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19

Contact Info

Product

Resources

About